Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 603-520-1 | CAS number: 131807-57-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3465 (90-Day Inhalation Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
Test material
- Reference substance name:
- 5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione
- EC Number:
- 603-520-1
- Cas Number:
- 131807-57-3
- Molecular formula:
- C22H18N2O4
- IUPAC Name:
- 5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- Substance ID: Famoxadone TGAI
Lot #: ENBK-171342-006
Purity: 98.4%
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Details on species / strain selection:
- Rats have historically been used in safety evaluation studies for inhalation toxicity testing. The Crl:CD(SD) rat was selected based on consistently acceptable health status and on extensive experience with the strain at the test facility.
- Sex:
- male/female
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Mass median aerodynamic diameter (MMAD):
- 3.4 - 4 µm
- Geometric standard deviation (GSD):
- 1.9
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples taken from the faceplate and the reference port of the 100 mg/m³ exposure chamber demonstrated differences that were less than 20% from the overall mean aerosol concentration; therefore, the test substance atmospheres were considered to be homogenously distributed in the breathing zones of the animals; therefore, the use of the sampling ports for air sampling was considered adequate.
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- Each group of animals was exposed for 6 hours/day, 5 days/week, for 4 consecutive weeks for a total of 20 exposures
Doses / concentrationsopen allclose all
- Dose / conc.:
- 3 mg/m³ air (nominal)
- Dose / conc.:
- 15 mg/m³ air (nominal)
- Dose / conc.:
- 100 mg/m³ air (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no toxicologically significant clinical observations made during the study.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in mean body weights or mean body weight gains in this study.
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance-related hematology changes included decreased red cell mass parameters (red blood cell concentration (RBC), hematocrit (HCT) and hemoglobin concentration (HGB)) in females at 100 mg/m³. Associated with these changes, females at 100 mg/m³ also had increased mean corpuscular volume (MCV), red cell distribution width (RDW), and absolute reticulocyte count (ARET), indicative of a regenerative response. Males at 100 mg/m³ also exhibited an increased RDW. Of these hematology findings, the mild decreases in red cell mass parameters in females at 100 mg/m³ were considered adverse.
Additionally, females at 100 mg/m³ also had increased absolute monocyte (AMON), absolute large unstained cell (ALUC), and secondarily, total white blood cell (WBC) concentrations. These changes were considered non-adverse, and were considered secondary to hemolysis. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance-related clinical chemistry changes included increased sorbitol dehydrogenase concentration (SDH) in females at 15 and 100 mg/m³, which was considered secondary to hepatocellular injury, although microsomal enzyme induction may have contributed. Changes considered attributable to microsomal enzyme induction included minimal to mild increases in SDH, alanine aminotransferase concentration (ALT) and alkaline phosphatase concentration (ALKP) in males at 100 mg/m³ (with hepatocellular injury possibly contributing to the increased SDH and ALT), increased cholesterol concentration (CHOL) in males and females at 100 mg/m³, and possibly the increased albumin (ALB) and total protein (TP) concentrations in males and females at 100 mg/m³ (and females at 15 mg/m³). None of these changes in clinical chemistry parameters were considered adverse themselves, although the increased SDH in females at 100 mg/m³ was considered reflective of the adverse single cell necrosis observed microscopically in the liver.
- Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Urine volume was statistically significantly lower in males exposed to 15 mg/m³ and in females exposed to 3 or 15 mg/m³. pH was also statistically significantly lower in females exposed to 15 mg/m³. These changes were considered likely unrelated to treatment because they did not occur in an exposure-related pattern.
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance-related organ weight changes included increased liver weights in males and females at 100 mg/m³, and increased spleen weights in females at 100 mg/m³, compared to controls.
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test substance-related gross observations. All gross observations at necropsy were interpreted to be spontaneous changes typical of background findings in rats of this age and strain.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased liver weights in both sexes were observed at 100 mg/m³ and correlated with the microscopic finding of centrilobular hepatocellular hypertrophy observed in both sexes at ≥15 mg/m³. The hypertrophy was compatible with the non-adverse induction of hepatic microsomal enzymes. Additional test substance-related microscopic findings in the liver included increased hepatocellular single cell necrosis and mitoses in both sexes at 100 mg/m³, which correlated with the increased hepatocellular enzyme concentrations. These microscopic changes were indicative of increased hepatocyte turnover, and the hepatocellular single cell necrosis was considered adverse.
Test substance-related microscopic findings in the nose consisted of minimal goblet cell hypertrophy/hyperplasia in the septum and nasopharyngeal duct of both sexes at 100 mg/m³. This finding was consistent with inhalation exposure to a slight irritant, and was considered an adaptive response and non-adverse. Test substance-related microscopic findings in hematopoietic tissue included increased splenic extramedullary hematopoiesis and increased splenic pigment in males at 100 mg/m³ and females at ≥15 mg/m³, splenic sinusoidal dilatation in both sexes at 100 mg/m³, and bone marrow erythroid hyperplasia in females at 100 mg/m³. These findings correlated with increased spleen weights in females at 100 mg/m³ compared to controls. Additionally, individual female rats at 100 mg/m³ exhibited minimal hepatic extramedullary hematopoiesis and increased Kupffer cells. All of these findings were considered secondary to test substance-related adverse effects on red cell mass parameters as described for females at 100 mg/m³.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 15 mg/m³ air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical biochemistry
- haematology
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 15 mg/m³ air (nominal)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Rat 4 week Inhalation NOAEL: 15 mg/m³
- Executive summary:
The objective of this study was to evaluate the potential toxicity of the test substance (according to the guideline EPA OPPTS 870.3465) when administered by inhalation as a dust aerosol to male and female (nulliparous and non-pregnant) Crl:CD(SD) albino rats for 4 weeks. Four groups of 10 male and 10 female rats were exposed nose-only for 6 hours per day for 5 days per week over a period of 28 days to design concentrations of 0 (air control), 3.0, 15, and 100 mg/m³ test substance. The chamber aerosol atmosphere was generated by suspension of the test substance in air. The test substance was metered to an air source using K-tron twin screw volumetric feeders. High pressure air, metered to the air source by Brooks mass flow controllers, carried the resulting atmosphere into the exposure chamber. Chamber aerosol concentrations of the test substance were determined by gravimetric analysis for the 15 and 100 mg/m³ chambers. The air control and 3.0 mg/m³ concentrations were determined by desorbing the gravimetric filters in acetonitrile and analyzing the test substance concentration by HPLC/DAD analysis.
Animals were observed for clinical signs of toxicity at least once per day and weighed at least once per week. The approximate amount of food consumed by each animal over a weekly weighing interval was determined by weighing each feeder at the beginning and end of the interval and subtracting the final weight and the amount of spillage from the feeder during the interval from the initial weight. From these measurements, mean daily food consumption over the interval was determined.
Ophthalmology evaluations were conducted by a veterinary ophthalmologist 2 days prior to the initiation of exposures and on test day 25. The baseline examination was performed on all animals received for the study, prior to assignment to groups. Where possible, any animals with preexisting ophthalmology abnormalities were excluded from assignment to the study.
Following the final exposure, rats were fasted overnight, blood and urine samples were collected for clinical pathology evaluations, and the animals were euthanized for anatomic pathology assessment including gross examinations and histopathology. The mean determined airborne aerosol concentration by HPLC/DAD in the 0 mg/m³ (air control and the 3.0 mg/m³) exposure chambers were 0.0 ± 0.0 and 3.60 ± 1.4 mg/m³ (mean ± standard deviation of every sample collected). The 15 and 100 mg/m³ groups were exposed to gravimetrically determined mean concentrations of 16 ± 3.4 and 110 ± 19 mg/m³, respectively. The MMADs from all exposure groups ranged from 3.4 to 4.0 μm and the GSDs ranged from 1.9 to 2.6.
All animals survived to their scheduled necropsy. All rats displayed normal alerting response during all exposures. There were no toxicologically significant clinical signs or test substance related ophthalmologic findings observed in any rats in this study.
There were no statistically significant differences in mean weekly body weights, mean body weight gains, or cumulative food consumption between the air control and test substance exposed groups at the end of the exposure period. Additionally, there were no changes in coagulation or urinalysis parameters, and no gross observations at necropsy considered related to test substance exposure.
Test substance-related hematology changes included decreased red cell mass parameters (red blood cell concentration (RBC), hematocrit (HCT) and hemoglobin concentration (HGB)) in females at 100 mg/m³. Associated with these changes, females at 100 mg/m³ also had increased mean corpuscular volume (MCV), red cell distribution width (RDW), and absolute reticulocyte count (ARET), indicative of a regenerative response. Males at 100 mg/m³ also exhibited an increased RDW. In both sexes at 100 mg/m³, these changes were associated with an increased bilirubin concentration (BILI), and microscopic findings of increased splenic extramedullary hematopoiesis, pigment and sinusoidal dilatation (as well as increased bone marrow erythropoiesis in females), suggestive of hemolysis. Of these hematology findings, the mild decreases in red cell mass parameters in females at 100 mg/m³ were considered adverse.
Additionally, females at 100 mg/m³ also had increased absolute monocyte (AMON), absolute large unstained cell (ALUC), and secondarily, total white blood cell (WBC) concentrations. These changes were considered non-adverse, and were considered secondary to hemolysis. Test substance-related clinical chemistry changes included increased sorbitol dehydrogenase concentration (SDH) in females at 15 and 100 mg/m³, which was considered secondary to hepatocellular injury, although microsomal enzyme induction may have contributed. Changes considered attributable to microsomal enzyme induction included minimal to mild increases in SDH, alanine aminotransferase concentration (ALT) and alkaline phosphatase concentration (ALKP) in males at 100 mg/m³ (with hepatocellular injury possibly contributing to the increased SDH and ALT), increased cholesterol concentration (CHOL) in males and females at 100 mg/m³, and possibly the increased albumin (ALB) and total protein (TP) concentrations in males and females at 100 mg/m³ (and females at 15 mg/m³). None of these changes in clinical chemistry parameters were considered adverse themselves, although the increased SDH in females at 100 mg/m³ was considered reflective of the adverse single cell necrosis observed microscopically in the liver.
Increased liver weights in both sexes were observed at 100 mg/m³ and correlated with the microscopic finding of centrilobular hepatocellular hypertrophy observed in both sexes at ≥15 mg/m³. The hypertrophy was compatible with the non-adverse induction of hepatic microsomal enzymes. Additional test substance-related microscopic findings in the liver included increased hepatocellular single cell necrosis and mitoses in both sexes at 100 mg/m³, which correlated with the increased hepatocellular enzyme concentrations. These microscopic changes were indicative of increased hepatocyte turnover, and the hepatocellular single cell necrosis was considered adverse.
Test substance-related microscopic findings in the nose consisted of minimal goblet cell hypertrophy/hyperplasia in the septum and nasopharyngeal duct of both sexes at 100 mg/m³. This finding was consistent with inhalation exposure to a slight irritant, and was considered an adaptive response and non-adverse. Test substance-related microscopic findings in hematopoietic tissue included increased splenic extramedullary hematopoiesis and increased splenic pigment in males at 100 mg/m³ and females at ≥15 mg/m³, splenic sinusoidal dilatation in both sexes at 100 mg/m³, and bone marrow erythroid hyperplasia in females at 100 mg/m³. These findings correlated with increased spleen weights in females at 100 mg/m³ compared to controls. Additionally, individual female rats at 100 mg/m³ exhibited minimal hepatic extramedullary hematopoiesis and increased Kupffer cells. All of these findings were considered secondary to test substance-related adverse effects on red cell mass parameters as described for females at 100 mg/m³.
No test substance-related effects were observed at 3 mg/m³ in either sex.
Under the conditions of this study, the no-observed-adverse-effect level (NOAEL) for the test substance is considered to be 15 mg/m³ for male and female rats based on increased single cell necrosis in the liver of both sexes at 100 mg/m³ and decreased red cell mass parameters in female rats at 100 mg/m³.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.